



Universiteit
Leiden
The Netherlands

Farnesoid X receptor agonist for the treatment of chronic hepatitis B: a safety study

Erken, R.; Andre, P.; Roy, E.; Kootstra, N.; Barzic, N.; Girma, H.; ... ; Reesink, H.

Citation

Erken, R., Andre, P., Roy, E., Kootstra, N., Barzic, N., Girma, H., ... Reesink, H. (2021).
Farnesoid X receptor agonist for the treatment of chronic hepatitis B: a safety study.
Journal Of Viral Hepatitis, 28(12), 1690-1698. doi:10.1111/jvh.13608

Version: Publisher's Version

License: [Creative Commons CC BY-NC 4.0 license](#)

Downloaded from: <https://hdl.handle.net/1887/3276405>

Note: To cite this publication please use the final published version (if applicable).

ORIGINAL ARTICLE

Farnesoid X receptor agonist for the treatment of chronic hepatitis B: A safety study

Robin Erken¹  | Patrice Andre²  | Elise Roy³ | Neeltje Kootstra⁴  | Noëlie Barzic³ | Hugo Girma³ | Christian Laveille⁵ | Pauline Radreau-Pierini³ | Raphael Darteil³ | Jacky Vonderscher³  | Pietro Scalfaro³  | Pisit Tangkijvanich⁶  | Robert Flisiak⁷  | Henk Reesink⁸ 

¹Department of Gastroenterology and Hepatology, Amsterdam UMC, University of Amsterdam, Duivendrecht, The Netherlands

²Inserm U1111, CNRS UMR5308, Université Lyon 1, and Ecole Normale Supérieure de Lyon, Lyon, France

³Enyo Pharma SA, Lyon, France

⁴Amsterdam UMC, University of Amsterdam, Department of Experimental Immunology, Amsterdam Infection & Immunity Institute, University of Amsterdam, Amsterdam, Netherlands

⁵Calvagone, Liègues, France

⁶Center of Excellence in Hepatitis and Liver Cancer, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

⁷Klinika Chorób Zakaźnych I Hepatologii UMB, Uniwersytecki Szpital Kliniczny w Białymstoku, Białystok, Poland

⁸Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, The Netherlands

Correspondence

Henk W. Reesink, Leiden University Medical Center, Department of Gastroenterology and Hepatology, Albinusdreef 2, 2333 ZA Leiden, The Netherlands.
Email: h.w.reesink@lumc.nl

Funding information

The trial described in this manuscript was funded by Enyo Pharma

Abstract

The nuclear farnesoid X receptor (FXR) regulates bile acid homeostasis and is a drug target for metabolic liver diseases. FXR also plays an important role in hepatitis B virus (HBV) DNA transcription. *In vitro* and in mice, FXR agonist treatment leads to inhibition of viral replication and a decline in viral proteins, pregenomic RNA (pgRNA) and HBV DNA levels. We aimed to translate this to a clinical use by primarily evaluating the safety and secondary the anti-viral effect of Vonafexor, a FXR agonist, in chronic hepatitis B (CHB) patients. In total, 73 CHB patients were enrolled in a two-part Phase Ib double-blind, placebo-controlled trial. Patients were randomized to receive oral Vonafexor (100, 200 and 400 mg once daily, or 200 mg twice daily), placebo, or entecavir (Part A, $n = 48$) or to receive Vonafexor (300 mg once daily or 150 mg twice daily), or placebo, combined with pegylated-interferon- α 2a (Part B, $n = 25$) for 29 days. Patients were followed up for 35 days. Enrolled CHB patients were mostly HBeAg-negative. Vonafexor was overall well tolerated and safe. The most frequent adverse events were moderate gastrointestinal events. Pruritus was more frequent with twice-daily compared with once-daily regimens (56%–67% vs. 16%, respectively, $p < 0.05$). Vonafexor monotherapy of 400 mg once daily decreased HBsAg concentrations ($-0.1 \log_{10}$ IU/mL, $p < 0.05$), and Vonafexor/pegylated-IFN- α 2a combination therapy decreased HBcAg and pgRNA. In conclusion, Vonafexor was safe with a decline in HBV markers observed in CHB patients suggesting a potential anti-viral effect the therapeutic potential of which has to be evaluated in larger trials.

KEYWORDS

cccDNA transcription, farnesoid X receptor, HBV therapy, phase Ib, Vonafexor

Abbreviations: ALT, alanine aminotransferase; BA, bile acid; cccDNA, covalently closed circular DNA; CHB, chronic hepatitis B; FXR, farnesoid X receptor; HBcAg, hepatitis B core-related antigen; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; LDL, low-density lipoprotein; pgRNA, pregenomic RNA.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

© 2021 The Authors. *Journal of Viral Hepatitis* published by John Wiley & Sons Ltd.

1 | INTRODUCTION

Despite mass efforts in preventive vaccination, there are more than 250 million hepatitis B virus (HBV) carriers globally, with more than 880,000 deaths due to HBV-related liver disease every year.^{1,2} Functional cure of HBV is characterized by a sustained loss of the hepatitis B surface antigen (HBsAg) and undetectable HBV DNA after treatment.³ Currently, HBV treatments include suppressing viral replication with nucleoside or nucleotide analogues or interferon, but rarely lead to a functional cure.

Hepatitis B virus covalently closed circular DNA (cccDNA) in the nucleus of infected hepatocytes serves as the template for HBV replication. Targeting HBV cccDNA transcription is a potential route for disrupting viral replication,⁴ reducing the host viral load and circulating viral proteins.⁵ Several studies provide evidence that the farnesoid X receptor (FXR) in the nucleus of hepatocytes, which is the main bile acid (BA) regulator,^{6,7} may also promote cccDNA transcription.^{8–15} Furthermore, the BA transporter, sodium taurocholate co-transporting polypeptide (NTCP), acts as the HBV cell entry receptor through which HBsAg and BA compete for cellular entry.¹⁶ As more viruses enter via the NTCP transporter, BA transport into hepatocytes is inhibited through a negative feedback process, leading to an increase in plasma BA levels and a decrease in the intrahepatic BA pool and resulting in alterations in FXR expression.^{8,17}

Previous studies have shown that FXR may be directly involved in HBV transcription and replication via viral gene regulation.^{13,14,18} FXR has been shown to interact with the viral protein HBx which affects HBV transcriptional regulation¹⁵ and several HBV regulating host factors.^{19–22} Finally, FXR was observed to be an HBV pro-viral factor whose activity is reversed by FXR agonists, leading to inhibition of viral transcription and subsequently reduction of viral proteins, pgRNA and HBV DNA both *in vitro* and *in vivo*.¹¹

We hypothesized that Vonafexor, a novel synthetic, orally active, non-bile salt, non-steroidal, carboxylic acid selective FXR agonist, may reduce the viral transcription activity in CHB patients. Vonafexor was identified *in vitro* as highly selective for FXR relative to other FXR agonists (eg GS9674, GW4064 and Ocaliva) and with properties better suited to clinical development. Moreover, Vonafexor has been shown to be less potent than alternative compounds,²³ which would support the safe long-term use in patients while maintaining an appropriate balance between its anti-HBV activity and its metabolic effects. Accordingly, we further explored the safety and anti-viral potential of Vonafexor in CHB patients in a Phase Ib clinical trial.

2 | MATERIALS AND METHODS

2.1 | Trial design

A phase Ib, multicentric (Australia, the Netherlands, Poland and Thailand), randomized, double-blind (Vonafexor or placebo. Entecavir and peg-IFN were not blinded), placebo-controlled, sequential two-part trial was conducted in CHB patients to explore the safety,

Significance Statement

Available treatments for chronic hepatitis B (CHB) may control, but rarely lead to a cure. The virus interacts in the hepatocyte with the bile acid homeostasis, which could become an important target for treatment. Here, we studied the investigational drug Vonafexor that interferes with the farnesoid X receptor, a main bile acid regulator. We evaluated for the first time Vonafexor in patients with CHB and found that it was well tolerated and reduced blood HBsAg levels. The potential of this new target for the treatment of CHB must be further determined in a larger trial with longer treatment durations.

tolerability and anti-viral activities of Vonafexor. The trial protocol and 3 amendments were approved by the institutional ethics committees of each trial centre, and the conduct of the trial was consistent with the Declaration of Helsinki and compliant with the International Council for Harmonization guidelines for Good Clinical Practice as well as with all local and national regulations. An informed consent form was signed by each patient before enrolment into the trial. The trial was conducted between December 2017 and August 2018.

2.2 | Participants

Patients aged 18–65 years with CHB for ≥ 6 months with a positive HBsAg test, HBV DNA >750 IU/ml, HBeAg-positive or -negative, alanine aminotransferase (ALT) $\leq 5 \times$ upper limit of normal (ULN) at screening were eligible for inclusion. Furthermore, patients had to be treatment-naïve or off treatment for more than 30 days before inclusion. Patients were excluded if they had relevant hepatic comorbidities or cirrhosis (details in Supplementary protocol).

2.3 | Procedures

In Part A, patients were randomly assigned using a block randomization algorithm to receive blinded oral Vonafexor (100 mg once daily (o.d.), 200 mg o.d., 200 mg twice daily (b.d.), or 400 mg o.d.), placebo, or open-label entecavir (0.5 mg o.d., Baraclude[®], Bristol-Myers Squibb, Clinton, NY) for 29 days (Figure 1). After establishing safety in Part A, patients in Part B were randomized to receive blinded Vonafexor (300 mg o.d. or 150 mg b.d.) or placebo for 29 days, combined with weekly subcutaneous injections of 180 μ g pegylated-interferon- $\alpha 2a$ (Peg-IFN $\alpha 2a$; Pegasys[®]; F Hoffman-La Roche, Basel, Switzerland). Patients had the option to participate in both Part A and Part B after a minimum wash-out period of 14 days between the two parts and complete eligibility assessment prior to each part. In both parts, safety assessments and blood collections were performed on days 1, 8, 15, 22, 29 and on the follow-up at day 35. Adverse events were monitored throughout the




FIGURE 1 Study design. EYP001, code for the international non-proprietary name Vonafexor; QD, once daily; B.D., twice daily

treatment period and follow-up and registered as MedDRA terms. Liver function tests (ALT, aspartate transaminase, total bilirubin and alkaline phosphatase) were scored using the AIDS-CTG severity grading scale.²⁴ Fibroblast growth factor-19 (FGF19), an intestinal BA regulatory protein and the BA precursor C4 (7 α hydroxy-4-cholesten-3-one), both important pharmacodynamic indicators of FXR modulation, were evaluated in all patients. Moreover, Vonafexor pharmacokinetics and HBV markers were evaluated in plasma samples (Table S1).

2.4 | Measurements

Hepatitis B surface antigen was measured with CLIA, Liaison XL HBsAg Quant (Diasorin, Saluggia, Italy), and HBV DNA levels were measured with COBAS 4800 PCR assay (F Hoffmann-La Roche, Rotkreuz Switzerland). HBV pgRNA levels were quantified using an in-house, PCR assay (DDL Diagnostic Laboratory, Rijswijk, The Netherlands) (range, 2.49–9.54 log₁₀ copies/ml) and hepatitis B core-related antigen (HBcrAg) levels using a chemiluminescent immunoassay (Lumipulse, Fujirebio, Tokyo, Japan), quantification range, 3–7 log₁₀ U/ml. Outcomes were compared with placebo or standard treatment (entecavir or Peg-IFN α 2a).

2.5 | Statistical analyses

Baseline and on-treatment variables were compared between groups using repeated measures linear model with fixed terms for treatment, visit and visit-by-treatment. An unstructured variance-covariance matrix was generated using SAS[®] Proc Glimmix (SAS Institute, Cary N, USA). A paired sample t test or Wilcoxon signed-rank test was used for paired analyses. All *p*-values were two-sided, and *p*-values <0.05 were considered statistically significant. All statistical analyses were performed with SAS[®], Version 9.4 (SAS Institute, Cary, NC, USA).

3 | RESULTS

3.1 | Patient disposition and baseline characteristics

A total of 73 subjects were enrolled, of whom 48 were included in Part A and 25 in Part B (Figure S1). Ten patients participated in both parts. Four patients (3 in Part A and 1 in Part B) withdrew

prematurely because of adverse events: urticaria, rash, pruritus and pre-existing borderline QT prolongation missed during screening. Overall, male and female patients were evenly distributed the mean age of patients was 39.7 years (range, 19–63 years) (Table 1). Most (91.8%) patients were HBeAg-negative and 70% were treatment-naïve. Mean HBV DNA baseline (log₁₀ IU/ml) was 4.2 (SD, 1.5) and HBsAg (log₁₀ IU/ml) 3.5 (SD, 0.8). HBV genotype A was most common (overall 31.5%).

3.2 | Safety and adverse events

The proportion of patients with at least one treatment emergent adverse event (TEAE) was similar between patients treated with Vonafexor (70% in Part A, 82% in Part B) and placebo (63% in Part A, 75% in Part B). Most (83% in Part A, 74% in Part B) TEAEs were of mild intensity in both groups. The most frequent TEAEs were headache, pruritus and diarrhoea in Part A, and neutropenia, pyrexia and headache in Part B (Table 2). Adverse events led to early treatment withdrawal in four patients, 3 of which possibly attributed to Vonafexor treatment: urticaria (Vonafexor 400 mg o.d.), rash (Vonafexor 200 mg b.d.) and pruritus (Vonafexor 150 mg b.d. with Peg-IFN α 2a). In Part A, 3/24 patients treated with Vonafexor once daily had pruritus versus 6/9 patients for the twice-daily treatment; in Part B, pruritus occurred in 2/8 patients with once daily versus in 5/9 patients with twice-daily regimens. Overall, pruritus occurred with once-daily regimens in 15.6% patients (5/32) versus 61.1% patients (11/18) with twice-daily regimens (*p* < 0.05). One patient in each twice-daily group had a TEAE that was rated by the investigator as severe: one headache (Vonafexor 200 mg b.d. and one ALT elevation, Vonafexor 150 mg b.d. with Peg-IFN α 2a).

No serious TEAEs or deaths occurred during the study.

3.3 | Change in transaminases

In Part A, 15/33 patients treated with Vonafexor showed elevated ALT levels, most of which were of mild intensity per AIDS-CTG grading (grade 1 [1.25–2.5 \times ULN], *n* = 11). One patient with grade 3 (5–10 \times ULN) ALT increases with a total bilirubin of 1.4 \times ULN, which was similar to the baseline value. In Part B, 19 patients had elevated ALT levels: grade 1 [*n* = 9], grade 2 [2.5–5 \times ULN; *n* = 8], and grade 3 [*n* = 2], all of whom had normal bilirubin and INR levels. Transient

TABLE 1 Baseline characteristics of CHB patients

	Total (N = 73)	Part A (N = 48)	Part B (N = 25)
Sex, n (%)			
Female	34 (46.6)	24 (50)	10 (40)
Male	39 (53.4)	24 (50)	15 (60)
Age, years (SD)	39.7 (9.8)	39.8 (9.9)	39.3 (9.8)
Race, n (%)			
Asian	22 (28.2)	15 (31.3)	7 (28.0)
Black	11 (15.1)	8 (16.7)	3 (12.0)
White	40 (54.8)	25 (52.1)	15 (60.0)
HBeAg status, n (%)			
Negative	64 (91.8)	45 (93.8)	19 (76)
Positive	9 (8.2)	3 (6.2)	6 (24)
Anti-HBeAg status, n (%)			
Negative	8 (11.0)	3 (6.3)	5 (20.0)
Positive	62 (84.9)	43 (89.6)	19 (76.0)
Unknown	3 (4.1)	2 (4.2)	1 (4.0)
HBV genotype, n (%)			
A	23 (31.5)	15 (31.3)	8 (32.0)
B	8 (11.0)	5 (10.4)	3 (12.0)
C	10 (13.7)	7 (14.6)	3 (12.0)
D	7 (9.6)	5 (10.4)	2 (8.0)
E	4 (5.5)	3 (6.3)	1 (4.0)
Unknown	21 (28.8)	13 (27.1)	8 (32.0)
Alanine transaminase, U/L (SD)	29 (16)	28 (12)	31 (23)
HBV DNA, log ₁₀ IU/ml (SD)			
HBeAg-positive	7.42 (1.56)	7.55 (0.78)	7.36 (1.91)
HBeAg-negative	3.71 (0.77)	3.80 (0.79)	3.50 (0.68)
HBsAg, IU/ml (SD)			
HBeAg-positive	4.02 (1.12)	4.09 (0.40)	3.98 (1.39)
HBeAg-negative	3.47 (0.67)	3.41 (0.68)	3.61 (0.63)
HBV RNA, copies/ml (SD)			
HBeAg-positive	6.06 (1.19)	6.15 (0.75)	6.02 (1.42)
HBeAg-negative	0.85 (1.79)	1.10 (1.74)	0.24 (1.80)
HBcrAg, log ₁₀ U/ml (SD)			
HBeAg-positive	7.48 (0.65)	7.77 (0.23)	7.34 (0.77)
HBeAg-negative	2.17 (1.66)	2.36 (1.68)	1.72 (1.56)

Abbreviations: HBcrAg, hepatitis B core-related antigen; HBeAg, hepatitis B envelope antigen; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; SD, standard deviation.

elevations ($n = 2$) or decline ($n = 2$) in HBV DNA levels ranging approximately between +1 and -2 log₁₀ IU/ml during treatment was seen in the patients with ALT elevations (Figure 2). The ALT elevations in these patients were not dose-related and ALT declined despite continuous Vonafexor administration in two of the four patients.

3.4 | Pharmacokinetics and pharmacodynamics

Vonafexor C_{max} increased less the dose proportional and T_{max} was 2 h (Table S2). The systemic drug exposure over time (AUC_{0-6h}) was also dose-dependent in patients who received Vonafexor once daily. Twice-daily dosing did not increase AUC_{0-6h} or C_{max} compared with once-daily regimens. Both AUC and C_{max} decreased on days 8 and 15 compared with day 1, with lower concentrations at days 15 and 29 than at days 1 and 8 for each dosing regimen. No statistical significance for most values was reached because of high inter-individual variation (CV 50%–70%).

Plasma C4 concentrations decreased at day 1, 6 h after dosing in all Vonafexor groups, but increased at all visits in the placebo and entecavir groups (Figure S2). The BA absorption response marker, FGF19, increased significantly at 6 h post-dose in all groups but to a larger extent for Vonafexor compared with control groups (Figure S3). Remarkably, the Vonafexor-induced FGF19 increase was more pronounced during the last two weeks of treatment compared with the first two weeks of treatment (p -value < 0.05).

3.5 | Impact on LDL

The low-density lipoprotein (LDL) increased by 39% ($p = 0.01$) from baseline to day 29 with Vonafexor 200 mg b.d., but did not significantly change over time for patients who received Vonafexor o.d. (6%–13%), entecavir (14%) or placebo (-2.8%). Compared with baseline, LDL concentrations did not change significantly at day 29 in the Vonafexor +Peg-IFN α 2a group (6%–8%, p -value > 0.05) but decreased in the placebo +Peg-IFN α 2a group (-24%, $p < 0.01$).

3.6 | Vonafexor's effect on HBV

Plasma HBsAg concentrations significantly and steadily decreased overtime between day 1 and day 29 in the Vonafexor 400 mg monotherapy group (-0.10 log₁₀ IU/ml, $p = 0.002$) (Figure 3). No significant changes were seen with placebo (-0.04 log₁₀), entecavir (-0.04 log₁₀), Vonafexor 100 mg o.d. (-0.02 log₁₀), Vonafexor 200 mg o.d. (-0.02 log₁₀) or Vonafexor 200 mg b.d. (-0.02 log₁₀) (all $p > 0.05$). In Part B on day 29, Vonafexor with Peg-IFN α 2a-treated patients had statistically lower HBsAg concentrations compared with placebo with Peg-IFN α 2a: Vonafexor 150 mg b.d. (-0.17 log₁₀ IU/ml, $p = 0.004$) and Vonafexor 300 mg O.D. (-0.12 log₁₀ IU/ml, $p = 0.040$) (Figure 3). The difference between HBsAg concentrations in the Vonafexor-treated groups compared with placebo was due to the HBsAg increase between day 1 and day 29 (0.12 log₁₀ IU/ml, $p = 0.004$) seen with placebo +Peg-IFN α 2a-treated patients only (Figure 3). HBV DNA levels did not change over time in any of the Vonafexor monotherapy groups (Figure 4) but decreased significantly and similarly in all patient groups treated with Peg-IFN α 2a (-1.80 log₁₀ IU/ml with Vonafexor 150 mg twice daily, -2.23 log₁₀ IU/

TABLE 2 Frequencies of patients with treatment-related adverse events.

MedDRA preferred term	Part A					Part B			
	Vonafexor 100 mg o.d. (N = 7)	Vonafexor 200 mg o.d. (N = 8)	Vonafexor 200 mg b.d. (N = 9)	Vonafexor 400 mg o.d. (N = 9)	Entecavir 0.5 mg o.d. (N = 7)	Placebo (N = 8)	Vonafexor 300 mg o.d. + Peg-IFN α 2a (N = 8)	Vonafexor 150 mg b.d. + Peg-IFN α 2a (N = 9)	Placebo + Peg-IFN α 2a (N = 8)
Patients with at least one TEAE, n (%)	4 (57)	2 (25)	9 (100)	8 (89)	4 (57)	5 (63)	6 (75)	8 (89)	6 (75)
Headache	3 (43)	1 (13)	1 (11)	4 (44)	0	1 (13)	3 (38)	3 (33)	4 (50)
Pruritus	1 (14)	1 (13)	6 (11)	1 (44)	0	0	2 (25)	5 (56)	0
Diarrhoea	1 (14)	0	1 (11)	4 (44)	1 (14)	1 (13)	3 (38)	1 (11)	1 (13)
Transaminase elevated	2 (29)	2 (25)	1 (11)	0	0	0	1 (13)	2 (22)	2 (25)
Abdominal pain	2 (29)	0	1 (11)	1 (11)	0	0	0	0	0
Myalgia	0	0	1 (11)	0	0	2 (25)	3 (38)	2 (22)	4 (50)
Insomnia	0	0	0	0	2 (25)	0	0	0	0
Fatigue	0	0	2 (22)	0	0	0	1 (13)	2 (22)	0
Neutropenia	0	0	0	0	0	0	4 (50)	5 (56)	0
Leukopenia	0	0	0	0	0	0	2 (25)	2 (22)	1 (13)
Pyrexia	0	0	0	0	0	0	5 (63)	3 (33)	4 (50)
Nausea	0	1 (13)	1 (11)	0	0	0	2 (25)	1 (11)	1 (13)
Decreased appetite	0	0	0	0	0	0	2 (25)	0	0
Musculoskeletal pain	0	0	0	0	0	0	0	2 (22)	0
Asthenia	0	0	0	0	0	0	0	1 (11)	2 (25)

Note: Only the most frequent treatment-related adverse events are shown (>20% of patients in any treatment group). B.D., twice daily; Peg-IFN α 2a; pegylated-interferon α 2a; O.D., once daily.

#The dynamics and maximum (mean G/L, SD) neutrophil decrease was similar in all Part B groups: -2.1 (1.3) with Vonafexor 300 mg o.d. + Peg-IFN α 2a, -3.3 (1.5) with Vonafexor 150 mg BID + Peg-IFN α 2a, and -2.4 (1.3) with placebo + Peg-IFN α 2a.

FIGURE 2 ALT and virology dynamics in patients with grade 3 or 4 ALT elevation. Treatment allocations per patient: S21-017, 100 mg Vonafexor once daily; S21-018, 200 mg Vonafexor once daily; S21-022, 150 mg Vonafexor twice daily +Peg-IFN α 2a; S42-011, 150 mg Vonafexor twice daily +Peg-IFN α 2a. ALT, alanine transaminase; Peg-IFN α 2a, pegylated-interferon α 2a. Dotted lines are HBV DNA changes and filled lines are ALT changes





FIGURE 3 Change in circulating HBsAg in patients after a 4-week Vonafexor treatment. Mean changes (SD) from day 1 baseline to day 35 of HBsAg (log₁₀ IU/ml). Groups were treated with Vonafexor (red lines), placebo (grey, straight line, circle) or entecavir (blue, straight line, rhombus). Vonafexor 100 mg once daily (straight line square); Vonafexor 200 mg once daily (straight line, triangle); Vonafexor 400 mg once daily (straight line, circle); Vonafexor 200 mg twice daily (straight line, cross); Vonafexor 300 mg daily combined with Peg-IFN α 2a (dotted line, rhombus); Vonafexor 150 mg twice daily combined with Peg-IFN α 2a (dotted line, square); placebo with Peg-IFN α 2a (dotted line, circle). HBsAg, hepatitis B surface antigen. Significance: *indicates $p < .05$ for change from baseline. # indicates $p < .05$ vs. placebo. o indicates $p < .05$ for change from baseline and vs. Placebo

ml with Vonafexor 300 mg once daily, and $-2.35 \log_{10}$ IU/ml with placebo [all $p < 0.001$] (Figure 4). HBV pgRNA (Figure S4) and HBcrAg (Figure S5) were measured as surrogate markers for cccDNA transcription. At baseline, most patients had detectable serum concentrations of HBV pgRNA and HBcrAg, respectively 38/48 [79.2%] and 35/48 [72.3%] patients in Part A, and 15/25 [60.0%] and 17/25 [68.0%] patients in Part B. In all monotherapy groups of Part A, pgRNA and HBcrAg levels did not change significantly. In Part B, HBcrAg and pgRNA levels in the Vonafexor 300 mg once daily +Peg-IFN α 2a group declined significantly (p -value < 0.05) at day 29 compared with baseline, and HBcrAg significantly (p -value < 0.05)

compared with placebo, suggesting a possible synergy between Vonafexor and Peg-IFN α 2a on HBcrAg and HBV pgRNA (Figure S5).

4 | DISCUSSION

This study explored the safety and for the first time the anti-viral effect of FXR targeting agonist Vonafexor in CHB patients. Overall, Vonafexor was well tolerated. The safety profile showed no significant unexpected adverse events in CHB patients over the 4-week treatment course as monotherapy or in combination with




FIGURE 4 Change in circulating HBV DNA in patients after a 4-week Vonafexor treatment. Mean changes (SD) from day 1 baseline to day 35 of HBV DNA (log₁₀ IU/ml). Groups were treated with Vonafexor (red lines), placebo (grey, straight line, circle) or entecavir (blue, straight line, rhombus). Vonafexor 100 mg once daily (straight line square); Vonafexor 200 mg once daily (straight line, triangle); Vonafexor 400 mg once daily (straight line, circle); Vonafexor 200 mg twice daily (straight line, cross); Vonafexor 300 mg daily combined with Peg-IFNα_{2a} (dotted line, rhombus); Vonafexor 150 mg twice daily combined with Peg-IFNα_{2a} (dotted line, square); placebo with Peg-IFNα_{2a} (dotted line, circle). HBV, hepatitis B virus. Significance: *indicates $p < .05$ for change from baseline. #indicates $p < .05$ vs. placebo. o indicates $p < .05$ for change from baseline and vs. Placebo

Peg-IFNα_{2a}. Furthermore, signs of a possible anti-viral effect of Vonafexor were observed as HBsAg decline in part A and changes in HBcrAg and pgRNA levels in part B of the study.

An adverse event of special interest was the prevalence of pruritus which was low to similar in once-daily regimens (16%) compared observations with other FXR agonists (14%–40%).^{25–27} Interestingly, however, pruritus was seen significantly more frequently when Vonafexor was administered twice daily (56%–67%). This difference could not be explained by plasma concentrations of Vonafexor, since the peak levels were lower in the twice-daily groups compared with the equivalent once-daily groups and the AUCs were similar. In addition, no dose-related effect was observed for pruritus. When analysing bile acid changes, we found no association with pruritus. C₄, the pharmacological marker reflecting FXR target engagement and key bile acid precursor metabolite, had similar reduced plasma levels after twice-daily compared with once-daily dosing regimens. Increase of the BA absorption response marker FGF19 after dosing was also similar for the two dosing groups. As pruritus is not directly associated with specific serum BA thresholds, a possible hypothesis for the increased pruritus might be related to the BA circadian physiology. Pruritus may potentially decrease medication adherence; therefore, twice-daily regimens of Vonafexor will not be tested further in future trials.

In four subjects, asymptomatic transient elevations of ALT grade 3/4 were seen. These flares were considered as possibly therapeutic transaminase flares.^{28,29} Two of the subjects receiving Vonafexor in monotherapy experienced an initial transient elevation of HBV DNA followed by ALT elevation; however, the increase was followed by a decrease in both ALT and HBV DNA. By contrast, two patients in the Peg-IFNα_{2a} combination group had a less recognizable pattern,

where HBV DNA decrease occurred randomly. ALT elevation in Peg-IFNα_{2a} treatment for 48 weeks is associated with favourable treatment outcome.³⁰ Speculation on what this means for Peg-IFNα_{2a} treatment in combination with Vonafexor is not possible due to the limited number of patients and short treatment duration in this phase 1 study. No association between the observed ALT, HBV DNA changes and hepatotoxicity in relation to different Vonafexor doses or treatment combinations was seen. Importantly, no Hy's law criteria were met³¹ and all patients did not show clinical or other laboratory abnormalities.

Although this trial was not powered to assess a clinically relevant decrease in viral markers, we observed a significant decrease of HBsAg levels in the highest monotherapy dose. Most treated patients were HBeAg-negative, a status correlated with high levels of integrated HBV DNA that can also produce HBsAg.³² As a consequence, the HBsAg decrease induced by Vonafexor could partially be masked by HBsAg production from the integrated genome. The observed HBsAg decline was small and occurred in a very short treatment period; also, the outcomes were of the same order of magnitude as HBsAg changes observed with other exploratory anti-HBV agents.³³ Further HBsAg decline may be expected with a longer treatment duration. HBsAg levels at day 29 in patients treated with Vonafexor and Peg-IFNα_{2a} were not decreased compared with baseline but interestingly were lower compared with the placebo group. It is known that Peg-IFNα_{2a} can induce an HBsAg increase in the first few weeks of treatment,³⁴ in particular known to occur in CHB patients infected with HBV genotype D. Such an increase was observed in the placebo group but not in patients treated with Vonafexor +Peg-IFNα_{2a}. This difference may be attributed to an anti-viral effect of Vonafexor on top of Peg-IFNα_{2a}.

A significant decrease in HBcrAg and pgRNA levels when combining Vofaxefor with Peg-IFN α 2a was also observed. This observation suggests a direct impact of Vofaxefor on viral transcription in the hepatocytes of CHB patients. However, because of the small sample size, the heterogeneity of patients participating in this trial and the relatively high limit of quantification of these viral markers, our results must be interpreted with caution. It is furthermore noteworthy that, unlike with Peg-IFN α 2a and entecavir, we did not observe a change in the viral load with Vofaxefor monotherapy. A possible explanation is that the Vofaxefor mechanism of action includes disruption of HBV pgRNA transcription not translating into relevant viral particle reduction because of the short treatment duration, while interferon's multifaceted mechanism of action includes a direct interaction with the HBV cccDNA more rapidly translating into viral load decrease. Accordingly, a longer duration of treatment with Vofaxefor monotherapy may eventually reduce the viral load. Based on the pgRNA and HBcrAg reduction, which positively correlates with intrahepatic transcriptional activity of liver cccDNA, Vofaxefor is to be further studied in combination with Peg-IFN α 2a over a longer duration to achieve clinically meaningful outcomes.

In conclusion, our clinical trial showed that Vofaxefor is safe, both as monotherapy and when combined with Peg-IFN α 2a. Signs of a potential anti-viral effect were seen in the highest dose of monotherapy and when combining Vofaxefor with Peg-IFN α 2a. Additional studies with a longer treatment duration may provide further evidence for efficacy. Vofaxefor is one of the few compounds which target non-viral host factors and may therefore be of value in future multi-therapy efforts aiming to achieve higher functional cure rates in CHB.

ACKNOWLEDGEMENTS

The authors thank the patients and their families, the investigators and site staff (Pr Stephen Riordan, Dr Wendy Cheng, Pr Kittyod Poovorawan, Pr Krzysztof Tomasiewicz, Dr Paweł Pabjan and Pr Włodzimierz Mazur), the Data Safety Monitoring Committee (Pr Peter LM Jansen, Dr Edmund Tse, Mr Patrick Lim and Ms Barbara Francis) and the clinical operations team (Gabriel Kremmidiotis, Sandrien Louwaars, Annemieke Hatzmann, Agnieszka Olek, Małgorzata Łokociejewska, Khajirat Netnee and Chayanont Chaimongkol). Medical writing support was provided by Dr. Julie Harriague of 4clinics and Dr. Artin Karapet of LyonaPharm and funded by Enyo Pharma.

CONFLICT OF INTEREST

ER, NB, HG, PRP, RD, JV and PS are employees of Enyo Pharma. PA, CL and HWR have received consulting fees from Enyo Pharma. Financial support from the French Agence Nationale de la Recherche sur le sida et les Hépatites Virales (ANRS) to PA and CR. RE, NK, PT and RF declare no conflict of interest.

AUTHOR CONTRIBUTIONS

Guarantor of article: Henk Reesink. Specific author contributions: PA, CL, JV, PS, PT, RF and HWR conceived and designed the study.

PA, ER, NB and PS supervised the study. RE, PA, ER, NB, PRP, RD, PT, RF and HWR contributed to the acquisition of data. RE, PA, NK, HG, CL, PRP, RD, JV, PS and HWR contributed to the analysis and interpretation of data. ER and NB provided administrative, technical or material support. HG performed the statistical analysis. RE, PA, NK, HG and RD drafted the manuscript. All authors contributed to the critical revision of the manuscript for important intellectual content and approved the final version. PS had access to all the data and vouches for the integrity of the data analyses.

ORCID

Robin Erken  <https://orcid.org/0000-0003-1067-0502>

Patrice Andre  <https://orcid.org/0000-0002-5834-7395>

Neeltje Kootstra  <https://orcid.org/0000-0001-9429-7754>

Jacky Vonderscher  <https://orcid.org/0000-0003-4963-5632>

Pietro Scalfaro  <https://orcid.org/0000-0003-4908-8608>

Pisit Tangkijvanich  <https://orcid.org/0000-0002-2926-8671>

Robert Flisiak  <https://orcid.org/0000-0003-3394-1635>

Henk Reesink  <https://orcid.org/0000-0002-6199-9247>

REFERENCES

1. WHO. Global hepatitis report World Health Organisation; 2017.
2. Razavi-Shearer D, Gamkrelidze I, Nguyen MH, et al. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. *Lancet Gastroenterol Hepatol*. 2018;3(6):383-403.
3. European Association for the Study of the Liver 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. *J Hepatol*. 2017;67(2):370-398.
4. Allweiss L, Dandri M. The role of cccDNA in HBV maintenance. *Viruses*. 2017;9(6):156.
5. Höner zu Siederdisen C, Maasoumy B, Cornberg M. What is new on HBsAg and other diagnostic markers in HBV infection? *Best Pract Res Clin Gastroenterol*. 2017;31(3):281-289.
6. Kim I, Ahn SH, Inagaki T, et al. Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine. *J Lipid Res*. 2007;48(12):2664-2672.
7. Inagaki T, Choi M, Moschetta A, et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. *Cell Metab*. 2005;2(4):217-225.
8. Oehler N, Volz T, Bhadra OD, et al. Binding of hepatitis B virus to its cellular receptor alters the expression profile of genes of bile acid metabolism. *Hepatology*. 2014;60(5):1483-1493.
9. Li L, Oropeza CE, Kaestner KH, McLachlan A. Limited effects of fasting on hepatitis B virus (HBV) biosynthesis in HBV transgenic mice. *J Virol*. 2009;83(4):1682-1688.
10. Curtil C, Enache LS, Radreau P, et al. The metabolic sensors FXRalpha, PGC-1alpha, and SIRT1 cooperatively regulate hepatitis B virus transcription. *FASEB J*. 2014;28(3):1454-1463.
11. Mouzannar K, Fusil F, Lacombe B, et al. Farnesoid X receptor- α is a proviral host factor for hepatitis B virus that is inhibited by ligands in vitro and in vivo. *FASEB J*. 2018;33(2):2472-2483.
12. Radreau P, Porcherot M, Ramiere C, Mouzannar K, Lotteau V, Andre P. Reciprocal regulation of farnesoid X receptor alpha activity and hepatitis B virus replication in differentiated HepaRG cells and primary human hepatocytes. *FASEB J*. 2016;30(9):3146-3154.
13. Ramiere C, Scholtes C, Diaz O, et al. Transactivation of the hepatitis B virus core promoter by the nuclear receptor FXRalpha. *J Virol*. 2008;82(21):10832-10840.

14. Reese VC, Moore DD, McLachlan A. Limited effects of bile acids and small heterodimer partner on hepatitis B virus biosynthesis in vivo. *J Virol*. 2012;86(5):2760-2768.
15. Niu Y, Xu M, Slagle BL, et al. Farnesoid X receptor ablation sensitizes mice to hepatitis B virus X protein-induced hepatocarcinogenesis. *Hepatology*. 2017;65(3):893-906.
16. Yan H, Peng B, Liu Y, et al. Viral entry of hepatitis B and D viruses and bile salts transportation share common molecular determinants on sodium taurocholate cotransporting polypeptide. *J Virol*. 2014;88(6):3273-3284.
17. Lefebvre P, Cariou B, Lien F, Kuipers F, Staels B. Role of bile acids and bile acid receptors in metabolic regulation. *Physiol Rev*. 2009;89(1):147-191.
18. Reese VC, Oropeza CE, McLachlan A. Independent activation of hepatitis B virus biosynthesis by retinoids, peroxisome proliferators, and bile acids. *J Virol*. 2013;87(2):991-997.
19. Keasler VV, Hodgson AJ, Madden CR, Slagle BL. Enhancement of hepatitis B virus replication by the regulatory X protein in vitro and in vivo. *J Virol*. 2007;81(6):2656-2662.
20. Leupin O, Bontron S, Schaeffer C, Strubin M. Hepatitis B virus X protein stimulates viral genome replication via a DDB1-dependent pathway distinct from that leading to cell death. *J Virol*. 2005;79(7):4238-4245.
21. Decorsiere A, Mueller H, van Breugel PC, et al. Hepatitis B virus X protein identifies the Smc5/6 complex as a host restriction factor. *Nature*. 2016;531(7594):386-389.
22. van de Klundert M, van den Biggelaar M, Kootstra N, Zaaijer H. Hepatitis B virus protein X induces degradation of Talin-1. *Viruses*. 2016;8(10):281.
23. Darteil R, Joly S, Radreau P, et al. In vitro characterization of Eyp001 a novel, potent and selective FXR agonist entering phase 2 clinical trials in chronic hepatitis B. *Hepatology*. 2019;70(S1). Abstract 87.
24. Núñez M. Clinical syndromes and consequences of antiretroviral-related hepatotoxicity. *Hepatology*. 2010;52(3):1143-1155.
25. Neuschwander-Tetri BA, Loomba R, Sanyal AJ, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. *Lancet (London, England)*. 2015;385(9972):956-965.
26. Harrison SA, Bashir MR, Lee KJ, et al. A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis. *J Hepatol*. 2021;75(1):25-33.
27. Patel K, Harrison SA, Elkhashab M, et al. Cilofexor, a nonsteroidal FXR agonist, in patients with noncirrhotic NASH: A phase 2 randomized controlled trial. *Hepatology*. 2020;72(1):58-71.
28. Chang ML, Liaw YF. Hepatitis B flares in chronic hepatitis B: pathogenesis, natural course, and management. *J Hepatol*. 2014;61(6):1407-1417.
29. Fontana RJ, Avigan MI, Janssen HLA, et al. Liver safety assessment in clinical trials of new agents for chronic hepatitis B. *J Viral Hepat*. 2020;27(2):96-109.
30. Ghany MG, Feld JJ, Chang K-M, et al. Serum alanine aminotransferase flares in chronic hepatitis B infection: the good and the bad. *Lancet Gastroenterol Hepatol*. 2020;5(4):406-417.
31. Robles-Diaz M, Lucena MI, Kaplowitz N, et al. Use of Hy's law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury. *Gastroenterology*. 2014;147(1):109-118.e5.
32. Wooddell CI, Yuen MF, Chan HL, et al. RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg. *Sci Transl Med*. 2017;9(409):eaan0241.
33. Yuen M-F, Agarwal K, Gane EJ, et al. Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial. *Lancet Gastroenterol Hepatol*. 2020;5(2):152-166.
34. Wang K, Huang G, Chen Y, Wang Y. Hepatitis B surface antigen (HBsAg) kinetics in chronic hepatitis B patients during peginterferon treatment. *Med Sci Monit*. 2020;26:e921487-1-e921487-12.

SUPPORTING INFORMATION

Additional supporting information may be found in the online version of the article at the publisher's website.

How to cite this article: Erken R, Andre P, Roy E, et al. Farnesoid X receptor agonist for the treatment of chronic hepatitis B: A safety study. *J Viral Hepat*. 2021;28:1690-1698. <https://doi.org/10.1111/jvh.13608>